Arcus Biosciences, Inc. develops and commercializes cancer therapies in the United States. Its product pipeline includes Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company was incorporated in 2015 and is headquartered in Hayward, California.
Market Cap | 1.644 Billion | Shares Outstanding | 71.06 Million | Avg 30-day Volume | 1.271 Million |
P/E Ratio | 24.4514 | Dividend Yield | 0.0 | EPS | |
Price to Revenue | 4.3658 | Debt to Equity | 0.0 | EBITDA | 93.445 Million |
Price to Book Value | 2.7046 | Operating Margin | 17.4908 | Enterprise Value | 697.781 Million |
Current Ratio | 6.215 | EPS Growth | 0 | Quick Ratio | 5.939 |
1 Yr BETA | 1.6304 | 52-week High/Low | 39.75 / 16.74 | Profit Margin | 18.4417 |
Operating Cash Flow Growth | 282.6766 | Altman Z-Score | 2.4582 | Free Cash Flow to Firm | 365.58 Million |
Please sign in first
none
38.9 Thousand total shares from 10 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
ROSEN TERRY J CHIEF EXECUTIVE OFFICER |
|
4,331,993 | 2023-01-23 | 4 |
JAEN JUAN C. PRESIDENT |
|
1,732,822 | 2023-01-23 | 5 |
GOELTZ II ROBERT C. CHIEF FINANCIAL OFFICER |
|
201,641 | 2023-01-23 | 3 |
JARRETT JENNIFER CHIEF OPERATING OFFICER |
|
602,746 | 2023-01-23 | 6 |
NUYTEN DIMITRY SA CHIEF MEDICAL OFFICER |
|
214,700 | 2023-01-23 | 3 |
TANG CAROLYN C. GENERAL COUNSEL |
|
235,739 | 2023-01-23 | 4 |
|
27,925 | 2022-06-14 | 1 | |
|
209,510 | 2022-06-14 | 1 | |
|
920,555 | 2022-06-14 | 1 | |
|
26,900 | 2022-06-14 | 1 | |
|
59,252 | 2022-06-14 | 1 | |
|
20,900 | 2022-06-14 | 1 | |
|
40,503 | 2022-06-14 | 1 | |
|
0 | 2021-08-10 | 0 | |
GROSSMAN WILLIAM CHIEF MEDICAL OFFICER |
|
20,723 | 2021-06-16 | 0 |
|
13,913,029 | 2021-01-31 | 0 | |
|
0 | 2021-01-06 | 0 | |
|
0 | 2020-07-13 | 0 | |
BARKER JASON SEE REMARKS |
|
10,000 | 2020-06-04 | 0 |
|
0 | 2019-06-06 | 0 | |
|
0 | 2019-06-06 | 0 | |
HEMRAJANI REKHA SEE REMARKS |
|
0 | 2019-03-25 | 0 |
CHAN STEVEN SEE REMARKS |
|
0 | 2019-01-16 | 0 |
|
No longer subject to file | 2018-03-19 | 0 | |
|
3,125,312 | 2018-03-19 | 0 | |
|
1,924,474 | 2018-03-19 | 0 | |
|
No longer subject to file | 2018-03-19 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-25 17:49:05 -0500 | 2023-01-23 | A | 429,000 | a | 429,000 | direct | ||||||||||
2023-01-25 17:55:09 -0500 | 2023-01-23 | A | 138,200 | a | 138,200 | direct | ||||||||||
2023-01-25 17:55:09 -0500 | 2023-01-23 | A | 34,000 | a | 76,500 | direct | 0.1732 | 0.1732 | 2 | 0.0 | 1 | |||||
2023-01-25 17:53:58 -0500 | 2023-01-23 | A | 138,200 | a | 138,200 | direct | ||||||||||
2023-01-25 17:53:58 -0500 | 2023-01-23 | A | 34,000 | a | 63,441 | direct | 0.1732 | 0.1732 | 2 | 0.0 | 1 | |||||
2023-01-25 17:52:48 -0500 | 2023-01-23 | A | 138,200 | a | 138,200 | direct | ||||||||||
2023-01-25 17:52:48 -0500 | 2023-01-23 | A | 34,000 | a | 97,539 | direct | 0.1732 | 0.1732 | 2 | 0.0 | 1 | |||||
JARRETT JENNIFER - Director - Officer CHIEF OPERATING OFFICER |
2023-01-25 17:51:41 -0500 | 2023-01-23 | A | 185,900 | a | 185,900 | direct | |||||||||
JARRETT JENNIFER - Director - Officer CHIEF OPERATING OFFICER |
2023-01-25 17:51:41 -0500 | 2023-01-23 | A | 45,800 | a | 416,846 | direct | 0.1732 | 0.1732 | 2 | 0.0 | 1 | ||||
2023-01-25 17:50:28 -0500 | 2023-01-23 | A | 185,900 | a | 185,900 | direct | ||||||||||
2023-01-25 17:50:28 -0500 | 2023-01-23 | A | 45,800 | a | 324,682 | direct | 0.1732 | 0.1732 | 2 | 0.0 | 1 | |||||
2023-01-25 17:49:05 -0500 | 2023-01-23 | A | 105,700 | a | 469,123 | direct | 0.1732 | 0.1732 | 2 | 0.0 | 1 | |||||
2022-12-16 21:39:46 -0500 | 2022-12-16 | S | 10,983 | $30.66 | d | 244,233 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | |||
2022-12-16 21:44:26 -0500 | 2022-12-16 | S | 387 | $31.23 | d | 11,566 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | |||
2022-12-16 21:44:26 -0500 | 2022-12-16 | S | 2,066 | $30.66 | d | 11,953 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | |||
2022-12-16 21:42:53 -0500 | 2022-12-16 | S | 398 | $31.23 | d | 28,584 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | |||
2022-12-16 21:42:53 -0500 | 2022-12-16 | S | 2,125 | $30.66 | d | 28,982 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | |||
JARRETT JENNIFER - Director - Officer CHIEF OPERATING OFFICER |
2022-12-16 21:41:51 -0500 | 2022-12-16 | S | 2,603 | $31.23 | d | 147,609 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | ||
JARRETT JENNIFER - Director - Officer CHIEF OPERATING OFFICER |
2022-12-16 21:41:51 -0500 | 2022-12-16 | S | 13,879 | $30.66 | d | 150,212 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | ||
2022-12-16 21:40:45 -0500 | 2022-12-16 | S | 701 | $31.23 | d | 218,258 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | |||
2022-12-16 21:40:45 -0500 | 2022-12-16 | S | 3,735 | $30.66 | d | 218,959 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 | |||
2022-12-16 21:39:46 -0500 | 2022-12-16 | S | 2,060 | $31.23 | d | 242,173 | direct | -32.5139 | -33.6283 | 0.0 | 1 | -33.6283 | 6 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 22:15:03 UTC | 4.0599 | 0.2601 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 21:45:04 UTC | 4.0599 | 0.2601 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 21:15:04 UTC | 4.0599 | 0.2601 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 20:45:03 UTC | 4.0558 | 0.2642 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 20:15:04 UTC | 4.0558 | 0.2642 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 19:45:03 UTC | 4.0558 | 0.2642 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 19:15:03 UTC | 4.0558 | 0.2642 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 18:45:04 UTC | 4.0577 | 0.2623 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 18:15:03 UTC | 4.0577 | 0.2623 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 17:45:03 UTC | 4.0577 | 0.2623 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 17:15:04 UTC | 4.0577 | 0.2623 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 16:45:03 UTC | 4.0588 | 0.2612 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 16:15:03 UTC | 4.0588 | 0.2612 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 15:45:03 UTC | 4.0588 | 0.2612 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 15:15:04 UTC | 4.0588 | 0.2612 | 1200000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 14:45:04 UTC | 4.0588 | 0.2612 | 1200000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 14:15:03 UTC | 4.0588 | 0.2612 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 13:45:03 UTC | 4.0678 | 0.2522 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 13:15:03 UTC | 4.0678 | 0.2522 | 1300000 |
ARCUS BIOSCIENCES INC RCUS | 2023-01-27 12:45:03 UTC | 4.0678 | 0.2522 | 1300000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | RCUS | -1300.0 shares, $-3393.0 | 2022-09-30 | N-PORT |
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund | RCUS | -2817.0 shares, $-73692.72 | 2022-09-30 | N-PORT |
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | RCUS | -874.0 shares, $-22269.52 | 2022-10-31 | N-PORT |
Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund | RCUS | -333.0 shares, $-8484.84 | 2022-10-31 | N-PORT |